Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Mary Jo Laffler

Mary Jo Laffler oversees US commercial content for Informa’s pharmaceutical news publications, working with a group of talented reporters and editors covering business, commercial and clinical news. She brings 16 years of experience reporting on the pharmaceutical industry for the Pink Sheet and affiliated publications, serving previously as Bureau Chief for Clinical Development and Business News, managing editor of the Pink Sheet and as one of the first managing editors for the Pink Sheet DAILY. While wearing many hats has given Mary Jo a wide-ranging knowledge of the commercial and regulatory challenges facing the pharmaceutical industry, her specialty is in analyzing drug development news and R&D strategy.
Set Alert for Articles By Mary Jo Laffler

Latest From Mary Jo Laffler

Deal Watch: CSL Behring's Calimmune Buy Builds On Its Base & Adds Platform Tech

Acquisition of gene therapy company Calimmune expands on CSL Behring's hematology franchise and fits rare disease business model, plus adds platform tech with wide application for CSL's portfolio.

Deals M & A

Amgen Faces New ICER Roadblock To Repatha Reimbursement

The Institute for Clinical and Economic Review is lowering the value-based pricing benchmark for Amgen's PCSK9 inhibitor based on the results of the FOURIER cardiovascular outcomes trial – which was positive overall but did not show a reduction in CV mortality.

Cost Effectiveness Market Access

Merck & Co. Strengthening Its Strong Position In Immuno-Oncology

Additional data presented at ASCO support earlier use of Keytruda in key settings like first-line lung and bladder cancers and approval in new indications like triple-negative breast and gastric cancers. Competitor setbacks also clear the stage for Merck.

ImmunoOncology Research and Development Strategies

Value & Pricing Perspectives From ASCO, In Brief

Round-up of commentary on oncology drug value and costs during the American Society for Clinical Oncology annual meeting, including value frameworks, ways to lower drug costs and payer data.

Pricing Debate Health Technology Assessment

Loxo Sees Larotrectinib As Model Form Of Oncology Drug Development

The pivotal data presented at ASCO showed a 76% response rate for the TRK inhibitor in patients with TRK fusion abnormalities, but there's still a lot left to prove about the tissue-agnostic model of drug development.

Cancer Clinical Trials

Loxo's Larotrectinib Requires Paradigm-Change In Clinical Practice

The TRK inhibitor won over ASCO with deep and durable responses across 17 cancer types, but diagnostics will be the true test of the tumor-agnostic approach – and the focus of Loxo's commercial strategy.

Clinical Trials Personalized Medicine
See All